Abciximab: a reappraisal of its use in coronary care

Marco Valgimigli, Gianluca Campo, Matteo Tebaldi, Roberto Carletti, Chiara Arcozzi, Roberto Ferrari, Gianfranco PercocoCardiovascular Institute, Azienda Ospedaliera Universitaria S. Anna, Ferrara, Italy and Cardiovascular Research Centre, Salvatore Maugeri Foundation, IRCCS Gussago (BS), ItalyAbstra...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Marco Valgimigli, Gianluca Campo, Matteo Tebaldi, Roberto Carletti, Chiara Arcozzi, et al
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2008
Materias:	Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/d24a3bee3b564e68a1dd214b110a0006
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:d24a3bee3b564e68a1dd214b110a0006
record_format	dspace
spelling	oai:doaj.org-article:d24a3bee3b564e68a1dd214b110a00062021-12-02T02:36:21ZAbciximab: a reappraisal of its use in coronary care1177-54751177-5491https://doaj.org/article/d24a3bee3b564e68a1dd214b110a00062008-03-01T00:00:00Zhttp://www.dovepress.com/abciximab-a-reappraisal-of-its-use-in-coronary-care-a51https://doaj.org/toc/1177-5475https://doaj.org/toc/1177-5491Marco Valgimigli, Gianluca Campo, Matteo Tebaldi, Roberto Carletti, Chiara Arcozzi, Roberto Ferrari, Gianfranco PercocoCardiovascular Institute, Azienda Ospedaliera Universitaria S. Anna, Ferrara, Italy and Cardiovascular Research Centre, Salvatore Maugeri Foundation, IRCCS Gussago (BS), ItalyAbstract: Platelet reactivity plays a pivotal role in the pathogenesis of ischemic adverse events during and after acute coronary syndromes (ACS), and percutaneous coronary intervention (PCI). Glycoprotein (GP) IIb/IIIa inhibitors are the strongest antiplatelet agents currently available on the market and three different compounds, namely abciximab, tirofiban, and eptifibatide, have been approved for clinical use. Abciximab has been investigated in the clinical field far more extensively than the other GPIIb/IIIa inhibitors. Abciximab is an anti-integrin Fab fragment of a human &ndash; mouse chimeric monoclonal antibody with high affinity and a slow dissociation rate from the GP IIb/IIIa platelet receptor. Abciximab, given shortly before the coronary intervention, is superior to placebo in reducing the acute risk of ischemic complications (EPIC, EPISTENT, EPILOG trials); moreover, in the ISAR-REACT 2 study abciximab has been shown to reduce the risk of adverse events in patients with non ST-segment elevation ACS who are undergoing PCI even after optimal pre-treatment with 600 mg of clopidogrel. Finally, abciximab has been also used in abciximab-coated stent, with only bolus administration regimen and for direct intracoronary use with promising results that may extend and/or modify its current use in clinical practice in future.Keywords: abciximab, percutaneous coronary intervention, myocardial infarction Marco ValgimigliGianluca CampoMatteo TebaldiRoberto CarlettiChiara Arcozziet alDove Medical PressarticleMedicine (General)R5-920ENBiologics: Targets & Therapy, Vol 2008, Iss Issue 1, Pp 29-39 (2008)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine (General) R5-920
spellingShingle	Medicine (General) R5-920 Marco Valgimigli Gianluca Campo Matteo Tebaldi Roberto Carletti Chiara Arcozzi et al Abciximab: a reappraisal of its use in coronary care
description	Marco Valgimigli, Gianluca Campo, Matteo Tebaldi, Roberto Carletti, Chiara Arcozzi, Roberto Ferrari, Gianfranco PercocoCardiovascular Institute, Azienda Ospedaliera Universitaria S. Anna, Ferrara, Italy and Cardiovascular Research Centre, Salvatore Maugeri Foundation, IRCCS Gussago (BS), ItalyAbstract: Platelet reactivity plays a pivotal role in the pathogenesis of ischemic adverse events during and after acute coronary syndromes (ACS), and percutaneous coronary intervention (PCI). Glycoprotein (GP) IIb/IIIa inhibitors are the strongest antiplatelet agents currently available on the market and three different compounds, namely abciximab, tirofiban, and eptifibatide, have been approved for clinical use. Abciximab has been investigated in the clinical field far more extensively than the other GPIIb/IIIa inhibitors. Abciximab is an anti-integrin Fab fragment of a human &ndash; mouse chimeric monoclonal antibody with high affinity and a slow dissociation rate from the GP IIb/IIIa platelet receptor. Abciximab, given shortly before the coronary intervention, is superior to placebo in reducing the acute risk of ischemic complications (EPIC, EPISTENT, EPILOG trials); moreover, in the ISAR-REACT 2 study abciximab has been shown to reduce the risk of adverse events in patients with non ST-segment elevation ACS who are undergoing PCI even after optimal pre-treatment with 600 mg of clopidogrel. Finally, abciximab has been also used in abciximab-coated stent, with only bolus administration regimen and for direct intracoronary use with promising results that may extend and/or modify its current use in clinical practice in future.Keywords: abciximab, percutaneous coronary intervention, myocardial infarction
format	article
author	Marco Valgimigli Gianluca Campo Matteo Tebaldi Roberto Carletti Chiara Arcozzi et al
author_facet	Marco Valgimigli Gianluca Campo Matteo Tebaldi Roberto Carletti Chiara Arcozzi et al
author_sort	Marco Valgimigli
title	Abciximab: a reappraisal of its use in coronary care
title_short	Abciximab: a reappraisal of its use in coronary care
title_full	Abciximab: a reappraisal of its use in coronary care
title_fullStr	Abciximab: a reappraisal of its use in coronary care
title_full_unstemmed	Abciximab: a reappraisal of its use in coronary care
title_sort	abciximab: a reappraisal of its use in coronary care
publisher	Dove Medical Press
publishDate	2008
url	https://doaj.org/article/d24a3bee3b564e68a1dd214b110a0006
work_keys_str_mv	AT marcovalgimigli abciximabareappraisalofitsuseincoronarycare AT gianlucacampo abciximabareappraisalofitsuseincoronarycare AT matteotebaldi abciximabareappraisalofitsuseincoronarycare AT robertocarletti abciximabareappraisalofitsuseincoronarycare AT chiaraarcozzi abciximabareappraisalofitsuseincoronarycare AT etal abciximabareappraisalofitsuseincoronarycare
_version_	1718402377454714880

Abciximab: a reappraisal of its use in coronary care

Ejemplares similares